Revier Therapeutics is a Heidelberg University spinout developing first-in-class, orally available small molecules that selectively inhibit class IIa histone deacetylases (HDACs) to treat cardiometabolic disease. Its lead programs target heart failure with preserved ejection fraction (HFpEF) and atherosclerotic cardiovascular disease (ASCVD), conditions that together affect hundreds of millions of patients worldwide. The company launched publicly in August 2026 from Heidelberg, Germany with a EUR 6 million seed financing led by KHAN Technology Transfer Fund II.
1
Round
1
Industry
4
Tags
Aug 25, 2026
Latest raise
Funding activity · 1 round
Aug 25, 2026
EUR 6M
Seed
Led by KHAN Technology Transfer Fund II
Article coming soon.
Pricing
Public hubs orient you on the raise. Paid plans unlock live AI adoption signals across your market.
For individuals and small teams getting started with AI buyer intelligence.
$149
/month
Features
For outbound teams and agencies that need more coverage and faster signal cadence.
$249
/month
Features
Act on this raise
Funding is the starting point. VeilStrat shows whether capital is showing up as hiring, tools, and web activity you can sell into.
